<DOC>
	<DOC>NCT01429701</DOC>
	<brief_summary>Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity and impaired quality of life due specially pruritus and physical visible skin lesions. The purpose of this trial is evaluate the effectiveness of two different topic associations of drugs.</brief_summary>
	<brief_title>Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous</brief_title>
	<detailed_description>Study design: - Experiment duration: 22 days - 2 visits (days 0,7,15 and 22) - Reducing eczema area and severity index evaluation - Adverse events evaluation - Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<mesh_term>Benzocaine</mesh_term>
	<criteria>1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with acute or subacute dermatitis with a minimum of 3 symptoms. 1. Pregnancy or risk of pregnancy. 2. Lactation 3. Use of antiinflammatory or immunosuppressive drugs (last 30 days prior to the study). 4. Sunlight over exposure in the last 15 days. 5. Any pathology or past medical condition that can interfere with this protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Dermatitis, Atopic</keyword>
</DOC>